|
COPYRIGHT 2004 NewsRX
2004 JUL 5 - (NewsRx.com & NewsRx.net) -- Bristol-Myers Squibb Company (BMY) and Otsuka Pharmaceutical Co., Ltd., announced that the European Commission has granted marketing authorization for Abilify (aripiprazole), an antipsychotic medication, for the treatment of schizophrenia.
"Receiving marketing approval for Abilify in 25 nations of the European Union marks a significant milestone for Abilify and for both companies, bringing an important medicine one step closer to the millions of people in Europe living with schizophrenia," said Peter R. Dolan, chairman and chief executive officer, Bristol-Myers Squibb.
"For patients with schizophrenia, Abilify has a unique pharmacology among the atypical antipsychotics and has demonstrated proven efficacy with a comprehensive tolerability and safety...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
